c-MET Inhibitor in Advanced Solid Tumors With c-MET Gene Aberration
NCT05882292
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
ABN401
Sponsor
Yonsei University